scholarly journals iTRAQ-Based Quantitative Proteomic Analysis Identified HSC71 as a Novel Serum Biomarker for Renal Cell Carcinoma

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Yushi Zhang ◽  
Yi Cai ◽  
Hongyan Yu ◽  
Hanzhong Li
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Early Stage ◽  
Characteristic Curve ◽  
Serum Biomarker ◽  
Control Group ◽  
Serum Samples ◽  
Quantitative Proteomic Analysis

Renal cell carcinoma (RCC) is one of the most lethal urologic cancers and about 80% of RCC are of the clear-cell type (ccRCC). However, there are no serum biomarkers for the accurate diagnosis of RCC. In this study, we performed a quantitative proteomic analysis on serum samples from ccRCC patients and control group by using isobaric tag for relative and absolute quantitation (iTRAQ) labeling and LC-MS/MS analysis to access differentially expressed proteins. Overall, 16 proteins were significantly upregulated (ratio > 1.5) and 14 proteins were significantly downregulated (ratio < 0.67) in early-stage ccRCC compared to control group. HSC71 was selected and subsequently validated by Western blot in six independent sets of patients. ELISA subsequently confirmed HSC71 as a potential serum biomarker for distinguishing RCC from benign urologic disease with an operating characteristic curve (ROC) area under the curve (AUC) of 0.86 (95% confidence interval (CI), 0.76~0.96), achieving sensitivity of 87% (95% CI 69%~96%) at a specificity of 80% (95% CI 61~92%) with a threshold of 15 ng/mL. iTRAQ-based quantitative proteomic analysis led to identification of serum HSC71 as a novel serum biomarker of RCC, particularly useful in early diagnosis of ccRCC.

scholarly journals Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma

Oncotarget ◽  
2014 ◽  
Vol 5 (2) ◽  
pp. 506-518 ◽  
Author(s):  
Nicole M.A. White ◽  
Olena Masui ◽  
Leroi V. DeSouza ◽  
Olga Krakovska ◽  
Shereen Metias ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Diagnostic Markers ◽  
Quantitative Proteomic Analysis

scholarly journals Quantitative Proteomic Analysis in Metastatic Renal Cell Carcinoma Reveals a Unique Set of Proteins with Potential Prognostic Significance

2012 ◽  
Vol 12 (1) ◽  
pp. 132-144 ◽  
Author(s):  
Olena Masui ◽  
Nicole M. A. White ◽  
Leroi V. DeSouza ◽  
Olga Krakovska ◽  
Ajay Matta ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Prognostic Significance ◽  
Quantitative Proteomic Analysis

Label-free quantitative proteomic analysis reveals potential biomarkers and pathways in renal cell carcinoma

Tumor Biology ◽  
2014 ◽  
Vol 36 (2) ◽  
pp. 939-951 ◽  
Author(s):  
Zuohui Zhao ◽  
Fei Wu ◽  
Sentai Ding ◽  
Liang Sun ◽  
Zhao Liu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Label Free ◽  
Quantitative Proteomic Analysis ◽  
Potential Biomarkers

Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 585-585 ◽  
Author(s):  
Patrick Glen Pilie ◽  
Lijun Zhou ◽  
Christine B Peterson ◽  
Yang Peng ◽  
Guang Peng ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
In Silico ◽  
Renal Cell ◽  
Clear Cell ◽  
Early Stage ◽  
Gene Signature ◽  
Cell Renal Cell Carcinoma ◽  
Tumor Stages

585 Background: Clear cell renal cell carcinoma (ccRCC) displays genomic instability across all tumor stages, indicative of increased replicative stress and defects in DNA damage response (DDR) pathways including homologous repair (HR); however ccRCC does not display mutations in canonical DDR genes and advanced ccRCC is not traditionally sensitive to DNA damaging agents. We hypothesized that biallelic VHL loss is sufficient to cause HR deficiency (HRD) and that early stage ccRCC is more likely to display HRD than late stage disease. Methods: We performed whole-exome (WES) sequencing of 15 small ccRCC tumors to assess for mutational burden, mutational signature, and cancer-related driver gene mutations. We performed in silico genomic, transcriptomic, and proteomic analysis of tumors in KIRC TCGA to assess for HRD. Finally, we assessed HR efficiency as a product of biallelic VHL loss in engineered cell line models. Results: 15/15 early stage ccRCC had VHL mutations, approximately 100 additional mutations per tumor, but no common mutations found in KIRC TCGA. In silico analysis showed 67% of KIRC TCGA displayed HRD gene signature, and was significantly higher in stage I disease (p = 2.21e-08). Patients with VHL-mutated tumors are more commonly HRD than HR intact (HRI) (p = 0.03), with frameshift/nonsense variants in VHL more likely to result in HRD than missense variants (p = 0.02). Multivariate analysis showed HRD predicted for better overall survival compared to HRI (p < 0.0001). Proteomic analysis of KIRC TCGA revealed HRI samples had significantly higher protein expression of Rad51 and RAPTOR when compared to HRD samples. Lastly, etoposide-treated MEF Vhl-/- cell lines displayed reduced HR efficiency when compared to Vhl intact controls. Conclusions: Biallelic loss of VHL is sufficient to cause HRD. HRD gene signature predicts for significantly better OS in ccRCC patients, and early stage ccRCC is more likely to be HRD. mTOR/PI3K signaling pathway proteins are differentially expressed in HRI patient samples from TCGA compared to HRD, suggesting a possible role for these oncogenes driving a HRI phenotype. Treatment strategies combining PARP inhibitors with PI3K/mTOR inhibitors should be tested in advanced VHL-mutated ccRCC.

scholarly journals Quantitative proteomic analysis reveals sophisticated metabolic alteration and identifies FMNL1 as a prognostic marker in clear cell renal cell carcinoma

2021 ◽  
Vol 12 (21) ◽  
pp. 6563-6575
Author(s):  
Gui Ma ◽  
Zirui Wang ◽  
junyao Liu ◽  
Shengjun Fu ◽  
Lili Zhang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Prognostic Marker ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Quantitative Proteomic Analysis ◽  
Metabolic Alteration

scholarly journals iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma

2016 ◽  
Vol 10 (3) ◽  
pp. 210-219 ◽  
Author(s):  
Limin Zhang ◽  
Haowen Jiang ◽  
Gang Xu ◽  
Nan Chu ◽  
Ningxing Xu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Clear Cell ◽  
Diagnostic Markers ◽  
Cell Renal Cell Carcinoma ◽  
Quantitative Proteomic Analysis ◽  
Early Diagnostic

Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma

PROTEOMICS ◽  
2008 ◽  
Vol 8 (15) ◽  
pp. 3194-3203 ◽  
Author(s):  
Noboru Okamura ◽  
Taro Masuda ◽  
Akinobu Gotoh ◽  
Toshiro Shirakawa ◽  
Shuji Terao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Therapeutic Targets ◽  
Diagnostic Markers ◽  
Human Renal Cell Carcinoma ◽  
Quantitative Proteomic Analysis

359: Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Endostatin in Renal Cell Carcinoma Patients Compared to a Control Group

2005 ◽  
Vol 173 (4S) ◽  
pp. 98-98
Author(s):  
Richard E. Zigeuner ◽  
Cord Langner ◽  
Peter Rehak ◽  
Marco Auprich ◽  
Katja Lipsky ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Serum Levels ◽  
Control Group ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Identification of Proteins Differentially Expressed in the Conventional Renal Cell Carcinoma by Proteomic Analysis

2005 ◽  
Vol 20 (3) ◽  
pp. 450 ◽  
Author(s):  
Jeong Seok Hwa ◽  
Hyo Jin Park ◽  
Jae Hun Jung ◽  
Sung Chul Kam ◽  
Hyung Chul Park ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Differentially Expressed ◽  
Conventional Renal Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document